Bioequivalence of Dapagliflozin 10 mg Tablets Under Fed Conditions
Status:
Completed
Trial end date:
2021-01-15
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the bioequivalence between:
- Dapagliflozin 10 mg tablets from Jiangsu Hansoh Pharmaceutical Group Co., Ltd.,China;
and
- Farxiga® 10 mg tablets from AstraZeneca Pharmaceuticals LP, USA; after a single-dose in
healthy subjects under fed conditions. The secondary objective of this study is to
evaluate the safety and tolerability of the study treatments.